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Perhaps more so than in other areas of medicine and
surgery, the management of acute and chronic venous disease
remain somewhat diffuse. A wide variety of medical and sur-
gical specialties are responsible for the prevention, diagnosis,
and treatment of acute deep venous thrombosis (DVT), and
patients with chronic venous disease (CVD)may be managed
by primary care physicians, dermatologists, interventional ra-
diologists, phlebologists, general surgeons, vascular medicine
specialists, and vascular surgeons. Each may have a different
approach to venous disease depending on their practice de-
mographics, experience, and training. Furthermore, although
the standard of care for acute venous thromboembolism has
been established by randomized clinical trials and evidence-
based guidelines have been developed,1 outcomes such as the
post-thrombotic syndrome have received inadequate atten-
tion, potential adjuncts such as thrombolytic therapy have not
been adequately evaluated, and there remain problems with
widespread dissemination of the guidelines. In the case of
chronic venous disease, many treatment approaches are based
on observational data and have not been subjected to rigorous
trials. Furthermore, the current approaches to someproblems,
such as post-thrombotic deep venous incompetence and the
prevention of ulcer recurrence, remain inadequate.
Under the auspices of the American Venous Forum
(AVF), the 5th Pacific Vascular Symposium was envisioned
as a process to address many of the problems existing in our
understanding and management of acute and chronic ve-
nous disease. The goals of the meeting were to define the
current state of knowledge in acute and chronic venous
disease, and using this information as a baseline, to identify
areas of deficiency, establish priorities, and map the future
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84Sof venous disease with respect to needed research, profes-
sional and patient education, organization of the field, and
management of acute and chronic venous disease. This was
accomplished through a process of professionally facilitated
appreciative inquiry2 involving collaboration among ex-
perts from epidemiology and clinical trials, dermatology,
hematology, interventional radiology, phlebology, and vas-
cular medicine and surgery as well as representatives from
industry and the National Institutes of Health. The assem-
bled experts were organized into four groups addressing
acute venous disease, the hemodynamic and diagnostic
evaluation of venous disease, primary chronic venous dis-
ease, and secondary chronic venous disease. A final break-
out group, the International Compression Club, evaluated
the current status and future needs of medical compression
hosiery.
The current state of knowledge in each of these areas
has been reviewed in the previous sections of this supple-
ment and provided the basis for developing future priorities
for the field. Several of the priorities crossed group desig-
nations and are discussed first below. These are followed by
the individuals groups’ recommendations for advancing the
future of venous disease, both in terms of overall priorities
and specific initiatives that can be begun immediately.
ADVANCING THE ART AND SCIENCE OF
VENOUS DISEASE
Organizational initiatives
The American Venous Forum (AVF), with a few excep-
tions, is largely composed of vascular surgeons. However,
physicians from several specialties participate in the care of
patients with acute and chronic venous disease and more
cooperative efforts across key specialties are needed. Such
efforts need to include vascular surgeons, dermatologists,
hematologists, interventional radiologists, cardiologists,
and field specific scientific experts in areas such as basic
science, epidemiology, and genetics. Unless the quality of
scientific collaboration and functional infrastructure are
comprehensively improved and promoted (designated
“we” priorities), priorities referring to the delivery of med-
icine from the physician to the patient (“me” priorities) are
unlikely to advance effectively. Consistent with these goals,
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should direct efforts towards becoming a more broadly
inclusive organization. As part of its scientific mission, the
forum shouldmove to establish a clearinghouse for projects
related to venous disease, allowing experts to collaborate
on specific initiatives. Such measures could include devel-
opment of a nonprofit foundation to consolidate funding
from disparate sources. The focus should be on highest
quality evidence and credibility; this could be best achieved
by collaboration between healthcare organizations, gov-
ernment funding agencies, industry, and members of the
AVF and associated groups. A more unified, broadly inclu-
sive organization would build a culture of cooperation and
common purpose among venous specialists.
With the purpose of strengthening, consolidating, and
coordinating the resources of existing organizations; rais-
ing awareness about venous disorders among physicians
and the public; and fostering relationships among those
with an interest in all aspects of venous disease; formation of
a Joint Venous Council was recommended. Council mem-
bers would include representatives from themajor societies,
industry, government, and the public. This group might be
structured similar to the peripheral arterial disease (PAD)
coalition that has focused on issues relating to peripheral
arterial disease. A steering committee has been formed to
implement this proposal and will develop an organizational
framework, propose membership of the Joint Council, and
plan an agenda for the first meeting.
A second universal theme was the need to develop a
new training paradigm to properly train physicians in the
diagnosis, treatment, and investigation of the entire spec-
trum of venous disorders. There is a clear need for an
organized, evidence-based postgraduate venous curricu-
lum. The development of an “angiology” specialty was
suggested as a long-term goal to be discussed at future
meetings. Creation of dedicated venous clinics with accred-
itation standards and a focus on education would be part of
this project. Significant resources should also be devoted to
educating nonspecialists (especially in the primary care and
hospital settings) in the prevention of deep venous throm-
bosis and leg ulcers.
A global information system to facilitate reporting of
venous disease was also considered important in advancing
communication among investigators. Such a system could
be used to develop and implement longitudinal epidemio-
logic studies characterizing the demographic, environmen-
tal, anthropomorphic, and social factors that lead to devel-
opment of chronic venous disease in an international
population. It would be useful in standardizing clinical
trials of venous thrombosis, as well as evaluating drugs and
devices for the treatment of venous disorders. Such a system
could also improve the education of practicing physicians,
private and governmental health care agencies, and the
public.
Finally, all groups agreed to the need for increased
governmental recognition of the importance of venous
disease and innovative approaches to research funding in-corporating both private commercial investment and gov-
ernmental funding.
Clinical and research initiatives
The therapy of venous disorders must become more
organized and evidence-based and should include develop-
ment of better drugs for acute and chronic venous disease,
as well as refinement of existing surgical procedures and
development of new procedures and devices. Potential new
devices for the treatment of venous disease include im-
proved stenting systems, biodegradable filters, venous con-
duits, angiogenesis factors, artificial valves, and skin re-
placements. A better understanding of the interaction
among devices and the coagulation and inflammatory sys-
tems will be required to properly assess any new device.
Quality of life assessments must also be part of the evalua-
tion of any new drug, device, or therapeutic approach to
venous disorders, and the associated psychosocial problems
need to be more fully addressed. Finally, from a clinical
perspective, the development of integrated, multidisci-
plinary teams is essential in the treatment of patients with
more advanced manifestations of CVD.
ACUTE VENOUS THROMBOEMBOLISM
The acute venous disease study section was charged
with developing global programs to promote the awareness
and prophylaxis of venous thromboembolic disease (VTE)
as well as developing specific scientific projects to improve
present standards of care. Several sessions were devoted to
the identification of projects that would advance the treat-
ment of venous disease through emerging technologies in
clinical and basic science. From these discussions came
three specific research endeavors that could be imple-
mented in the next funding cycle. Many other potential
initiatives were discussed, with the goal of using this meet-
ing to launch future projects.
General priorities in acute venous thromboembolism
Several areas of need were identified and discussed in
enough detail to initiate corrective measures and scientific
studies in the near future. The need for a cooperative,
interdisciplinary approach to venous disease; the advan-
tages of a multidisciplinary, multicenter approach to re-
search; and the need for a partnership between governmen-
tal funding agencies and industry has been discussed above.
From an organizational standpoint a network of physicians
interested in clinical protocols and basic research is also
needed. This network should be internet-based and must
be responsive to government-sponsored requests for pro-
posals and industrial opportunities. Increased involvement
of the AVF research committee in coordinating a web
article repository, serving as a clearinghouse for Pacific
Vascular V reports, and organizing lifeline venous research
presentations is also needed.
From a research perspective, the basic mechanisms of
venous thrombosis initiation and resolution need to be
further investigated with the goal of designing future clin-
ical trials in a hypothesis driven manner. Crucial to further
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with therapies to improve and standardize patient care.
Specific research initiatives in acute venous
thromboembolism
Three specific research projects were identified as war-
ranting immediate attention and planning.
Strategies for early thrombus removal. Despite en-
couraging results from large multicenter registries3 and
small trials,4,5 there is a lack of randomized clinical trial data
supporting the use of early thrombus removal techniques in
the treatment of acute DVT and such strategies are not
routinely recommended by current consensus guidelines.1
There is a clear need for generalizeable, randomized clinical
trials comparing standard anticoagulation with “open vein”
strategies designed to remove thrombus early after presen-
tation with mechanical or pharmacological catheter-based
thrombolytic techniques. Such trials should be of an inter-
national, multicenter design with anatomic stratification
(iliofemoral vs femoropopliteal thrombosis) of patients.
The design should include a 1-year run-in period to bring
all centers online and perform early harm analysis. There
was consensus in allowing some latitude with respect to the
specific technique of thrombus removal (mechanical, phar-
macological, or combination) to accommodate improve-
ments in technology. Emphasis was placed on 5-year as well
as 1-year outcomes with respect to quality of life, rate of
recurrent VTE, and objective development of the post-
thrombotic syndrome.
It is notable that a similar initiative, comparing best
medical therapy vs best interventional strategy for throm-
bus removal, was recently designated the highest research
priority at a multidisciplinary consensus panel arranged
under the auspices of the Cooperative Alliance for Inter-
ventional Radiology Research (CAIRR) and the Society for
Interventional Radiology (SIR).6 The trial proposed by this
panel is currently in the initial development and funding
stages. The participants at the Pacific Vascular Symposium
broadly supported such a trial and agreed to assist in the
design and implementation of a definitive study as needed.
Defining the role of inferior vena cava (IVC) filters.
The safety of permanent filters, as well as the development
of retrievable filters, has led to their expanded use for a
number of perceived relative indications7,8 without sub-
stantial evidence to support such practices. Trials compar-
ing the use of permanent and retrievable IVC filters with
prophylaxis and DVT surveillance strategies in high-risk
patients (eg, trauma and intracerebral hemorrhage) are
desperately needed. The development and implementation
of such a trial would optimally involve the participation of
trauma surgeons and intensive care specialists. Trial end-
points should include survival, incidence of VTE, cost,
length of ICU and hospital stay, and device specific com-
plications such as IVC patency and filter migration.
Biomarkers in defining prognosis and determining
duration of anticoagulation after acute DVT. Prelimi-
nary data suggests that the levels of fibrinolytic inhibition
and activated coagulation are related to the extent of recan-alization.9 Furthermore, although the duration of antico-
agulation is currently based on the risk of recurrent VTE,
determined by randomized clinical trials,1 observational
data suggests that incomplete recanalization documented
by ultrasonography10,11 and persistently elevated D-Dimer
levels12 after discontinuing oral anticoagulants are impor-
tant risk factors for recurrence. There is a need for robust
management trials of specific markers of coagulation (D-
Dimer, thrombin-antithrombin complex, microparticles,
prothrombin fragment 1  2) and fibrinolysis (t-plasmin-
ogen activator and plasminogen activator inhibitor-1) in
determining the type and duration of therapy for acute
VTE. Endpoints would include thrombus extension, recan-
alization, and recurrent VTE. Biomarkers would be quan-
tified at presentation, 1 week prior to discontinuation of
therapy and 4 weeks following the completion of therapy.
Patients would be followed for at least 2 years to document
endpoints.
Other research priorities in acute DVT. Other stud-
ies proposed, but not developed in detail, included devel-
opment of a test or panel of tests (a “thrombochip”) to
stratify the risk of VTE and predict outcomes after acute
DVT. Such knowledge would permit interventions and
duration of therapy to be individualized based on genomic,
proteomic and serum biomarker profiles. Studies defining
the true natural history and appropriate management of
both secondary upper extremity DVT and proximal saphe-
nous thrombophlebitis are also needed. There is clearly no
consensus regarding the treatment of superficial thrombo-
phlebitis and a registry may be more appropriate than a
formal trial as an initial step. Projects including strategies to
promote DVT awareness and improve compliance with
established American College of Chest Physician (ACCP)
guidelines13 were also encouraged. Multicenter projects to
generate support for young investigators and to assist with




This group focused on unresolved issues and future
projects involving the diagnosis of acute and chronic ve-
nous disease. As venous diagnostic testing requires a thor-
ough understanding of venous physiology and hemody-
namics, this group was termed the diagnostics/
hemodynamics group. After preliminary discussions in
breakout groups, the diagnostics/hemodynamics group
developed plans and recommendations for research
projects relevant to venous diagnosis.
General priorities in venous diagnostics and
hemodynamics
The initial discussions of the diagnostics/hemodynam-
ics group were broadly focused and several ideas were
advanced. Future research should focus on the identifica-
tion of molecular, serologic, and genetic markers that may
be useful in detecting venous disease apriori, perhaps in
conjunction with targeted thrombophilia testing and as-
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might facilitate more individualized treatment of patients
with acute venous thrombosis and chronic venous disease
and aid in identifying the contribution of individual risk
factors to the overall risk of venous thrombosis.
Further work is needed to improve our understanding
of venous physiology, pathophysiology, and natural his-
tory. This is fundamental to improving diagnostic tests and
facilitating precise treatment of patients with venous disor-
ders. The development of a quantitative test for venous
obstruction and a global noninvasive surrogate measure of
ambulatory venous pressure are particular priorities. In
addition, there is a critical need to standardize existing
venous tests with respect to indications, testing protocols,
and normal ranges. A clear definition of what constitutes a
significant change in a testing parameter is particularly
needed in patients with advanced CVD who may undergo
interventions.
Specific research initiatives in venous diagnostics and
hemodynamics
Based on these preliminary deliberations, the following
projects have been identified as priorities in advancing our
understanding of venous hemodynamics and improving
diagnostic modalities.
Investigating venous disease evaluation and stan-
dardization of testing (INVEST). The goals of this
project are to standardize noninvasive testing for acute and
chronic venous disease; identify standard quality of life and
hemodynamic outcomes; and develop uniform testing pro-
tocols. As initially proposed, this project involves three
phases. First, the diagnostic modalities currently being
utilized in vascular laboratories must be determined. Po-
tential sources of data include the Intersocietal Commis-
sion for Accreditation of Vascular Laboratories (ICVAL)
database, which can be used to identify tests actually being
performed as well as the indications, protocols, and exam
and interpretation standards of various vascular laborato-
ries. The Center for Medicare and Medicaid Services
(CMS) can also be queried for ICD-9 and CPT codes to
define the range of tests performed, the indications for
testing, and the demographics of those ordering examina-
tions. Members of the venous societies can also be surveyed
for their testing practices in patients with acute and chronic
venous disease. Secondly, a comprehensive literature review
should be undertaken to examine the tests and standards
used in current venous research. Finally, appropriate soci-
etal representatives should evaluate the above data and a
consensus statement developed regarding protocols for
noninvasive venous testing, normal ranges, the definition
of significant within patient change, and recommended
examinations based upon common clinical presentations.
These suggestions would be added to the existing reporting
standards for venous disease.14-16
MR outflow obstruction of venous disease
(MOOVD). Magnetic resonance venography (MRV) is
among the most promising modalities in venous diagnostic
testing. This project aims to explore the use of MRV inassessing venous obstruction. Potential methods of interest
include CINE-gated MRV to quantify outflow obstruc-
tion. Soft tissue water content should also be evaluated as a
potential diagnostic measure. Pre- and post-therapy testing
will be performed along with blood tagging (eg, with
gadolinium) studies to evaluate venous inflow and outflow.
Assessment of reflux and symptomatic evaluation
(ARSE). This study proposes to evaluate the anatomic
patterns of reflux and hemodynamic parameters that most
accurately identify individual CEAP categories, forecast
disease progression to higher CEAP classes, and predict
response to therapy (quality of life, ulcer healing). Reflux
will be evaluated from the inguinal ligament to the ankle
using duplex ultrasonography and standing cuff deflation
methods.17 Diagnostic measurements will include duration
of reflux, reflux velocity, reflux volume, reflux velocity
index, and perhaps other as yet unknown parameters. An
Incompetent Valvular Severity Score will be developed to
quantify the overall severity of reflux. A multicenter design
is required to provide adequate patient numbers and insure
inclusion of patients with varying demographics. Subjects
with lymphedema, recent trauma, BMI 40, and previous
vein surgery would be excluded.
Duplex ultrasound in a multicenter study of acute
DVT (DUMSAD). Most validated strategies for the di-
agnosis of acute DVT have limited examination to com-
pression of the proximal veins and have required either
serial examinations18,19 or combined algorithms including
D-dimer measurement and clinical risk stratification.20-23
Despite encouraging preliminary data,24,25 the accuracy of
a single, technically adequate duplex scan, including the
calf veins, has not yet been sufficiently validated.
The purposes of this study are to evaluate the accuracy
of a single color flow duplex examination, including the calf
veins, in excluding acute DVT; to improve guidelines for
the diagnosis of acute DVT; and to define an adequate scan
technique. Subjects should have no prior history of DVT
and be clinically symptomatic. In addition to clinical and
demographic information, collected data will include phys-
ical examination (including calf circumference), clinical
probability scores, and D-dimer and CRP levels. Complete,
bilateral color flow duplex scans will be performed includ-
ing measurement of thrombus location, length, volume,
and echogenicity as well as venous diameter and wall thick-
ness. Subjects with negative scans but a high clinical prob-
ability of DVT will undergo serial imaging. As comparison
with venography would be difficult, this will be a manage-
ment trial with endpoints including the results of clinical
and ultrasound follow-up at 6 months.
Outcome relation to thrombus characteristics
(OTC). The purposes of this study are to evaluate the
natural history of DVT, including the development of
reflux, in relation to ultrasound characteristics of the
thrombus. Thrombus specific measurements will include
the extent and location of the thrombus, degree and length
of time to recanalization, grey-scale characteristics of the
thrombus, and the development of reflux and its timing.
Analysis will include the effects of type of anticoagulation
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of other adjuvant therapies, and serum markers of coagula-
tion, fibrinolysis, and inflammation.
PRIMARY CHRONIC VENOUS DISEASE
The working framework for the primary chronic ve-
nous disease group was subdivided into topics including
prevention, pathophysiology, diagnostics, research, and
treatment and intervention.
General priorities in primary chronic venous disease
The combination of declining health care budgets and
an increasing number of patients with CVD will soon
render the issue of funding care for complications of pri-
mary CVD critical. Population screening for early disease
will likely become indispensable in containing the socio-
economic repercussions of primary CVD by enabling
timely intervention and prevention of disease progression.
Control of associated risk factors; genetic interventions in
CVD-related aberrations; selective, safe and long-lasting
suppression of inflammatory processes; and national aware-
ness of primary CVD are also essential in disease preven-
tion.
Optimal treatment of CVD is currently hindered by
insufficient knowledge of the pathophysiology, including
the sentinel events preceding CVD progression and the
effects of inflammation, re-epithelialization, matrix deposi-
tion, and tissue remodeling. An improved understanding of
these pathophysiologic mechanisms, through clinical and
basic research, is critical to further advancements in disease
prevention and management.
Comprehensive, cost-effective, and minimally invasive
diagnostics must be developed to facilitate both early iden-
tification of CVD and quantification of the associated
pathophysiology. Three-dimensional, limb specific imag-
ing equipment providing accurate data on the anatomy,
hemodynamics, and cytochemical interactions can be envi-
sioned in the near future. Such progress would certainly
promote the development of new therapies optimized for
clinical efficacy, invasiveness, adverse effects and cost-effec-
tiveness. Treatment assisted by robotics, innovative drugs,
gene therapy, high-technology compression hosiery, and
endovalves would greatly improve currently available sur-
gical techniques.
Development of such therapies will require a thorough
reorganization of existing practices and institutions. There
is a clear need for evidence-based management protocols in
CVD. Geographic centers of clinical excellence, collectively
cooperative, and a Central Venous Disease Clearing House
(eg, National Institute for Venous Clinical Excellence)
might facilitate clinical and academic progress while safe-
guarding professional cohesiveness and ethical integrity.
Based upon these considerations, the following priori-
ties (in declining order) were proposed by the primary
chronic venous disease group.
(a) The development of minimally- or noninvasive tech-
niques for restoring vein function;(b) Enhancement of public and physician awareness of
primary CVD;
(c) Identification of important, quantifiable determinants
of outcome at the macro-/micro-circulation and tissue
levels;
(d) Identification of tissue markers and precursors of pri-
mary chronic venous disease development;
(e) Identification of genetic and environmental factors
leading to primary venous disease;
(f) The development of pharmaco- and physical-therapies
for primary chronic venous disease prevention and
treatment.
Specific research initiatives in primary chronic venous
disease
Core lab consortium and genetic database. A core
laboratory consortium to collect samples of blood, vein,
skin, and other pertinent tissues would foster working
relationships among investigators and expedite both clini-
cal and basic science research. Samples and de-identified
demographic data would be stored by the consortium and
made available to participating institutions. Academic in-
vestigators, the pharmaceutical industry, and other institu-
tions undertaking venous research or research linked to
venous specimens (internal medicine, rheumatology cardi-
ology, etc.) would have access to the tissue bank. Potential
targets for investigation would include proteonomics, eval-
uation of up-regulated or down-regulated genes, and in-
flammatory markers as well as their correlation with patho-
physiological and clinical data. An initial goal of collecting
specimens from 200 subjects, with targeted investigation of
several of these questions was proposed.
Endovenous valve repair. Despite the reported suc-
cess of primary venous valve repair,26-29 these procedures
are not widely performed, at least partly because the proce-
dures are perceived as complex with good results obtained
only in a few centers having extensive experience. There is a
clear need for a minimally- or noninvasive venoscopic valve
repair to restore vein function. Making use of advanced
stapling and suturing technology, this method would en-
able minimally invasive valve reconstruction, obviating the
need for complex open surgery or vein ablation. The par-
ticipation of industry would be required for design exper-
tise, funding, prototype development, feasibility assess-
ment, and animal testing.
Wireless, functional venous diagnostic tests (ISR-
VDS). Many currently available diagnostic tests (Duplex
ultrasonography, air plethysmography) require cumber-
some diagnostic equipment that limits their application
under truly physiological conditions. An innovative,
screenless, real-time, venous duplex system, (ISR-VDS)
would be a significant addition to the venous diagnostic
armamentarium. Such a system would optimally use wire-
less, real-time, three dimensional, color duplex technology,
delivered to the examiner through virtual reality eyewear
and allowing superimposition of images on the surgical or
endovascular field. Development of a system would likely
require assistance from the military, computer and ultra-
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and initial animal and human testing.
SECONDARY CHRONIC VENOUS DISEASE
Occurrence of the post-thrombotic syndrome after an
episode of acute DVT is related to both failure of recanali-
zation, with persistent venous obstruction, and the devel-
opment of valvular incompetence.30,31 Important priorities
in improving the care of patients with secondary chronic
venous disease include prevention, development of diag-
nostic tests to precisely identify sites of abnormal venous
function, and the development of technology to rectify
chronic obstruction and secondary valvular incompetence.
General priorities in secondary chronic venous disease
Advances in the treatment of acuteDVT are critical to the
prevention of the post-thrombotic syndrome. Early, complete
thrombus removal by mechanical, pharmacological, or surgi-
cal thrombectomy is likely an important adjunct in preventing
chronic obstruction as well as vein wall and valvular damage.
The need for multicenter, international randomized clinical
trials comparing catheter-directed thrombolysis, endovenous
mechanical thrombectomy, and surgical thrombectomy with
standard anticoagulation alone has been detailed above. The
development of oral thrombolytics and anti-inflammatory
drugs that inhibit vein wall/valve fibrosis would be ideal.
Finally, “thrombosis teams”, with significant expertise in this
field, should be organized at major healthcare centers.
It is known that previous deep venous thrombosis,
heredity, and occupational prolonged standing contribute
to the development of symptoms, but the pathophysiology
and genetic determinants of CVD are largely unknown.
Our current understanding of CVD suggests that is devel-
ops from the following sequence of events - initial pericap-
illary extravasation caused by inflammation is followed by
formation of a fibrotic perivascular cuff with vascular pro-
liferation, fibroblast recruitment, and fibrosis mediated by
matrix metalloproteinases (MMPs) and other protein-
ases.32-37 The capillary endothelium likely includes a mech-
anism that detects the hemodynamic changes produced by
venous hypertension. Drugs such as pentoxyphilline and
Daflon are believed to act by inhibiting leukocyte-endothe-
lium interactions and reducing tissue edema.38 However,
advances in pharmacotherapy and other approaches, such
as stem cell treatment, will be possible only through an
improved understanding of the pathophysiological mecha-
nisms underlying the progression from C0 to C6 disease.
This must include a better definition of the genetic basis of
chronic venous insufficiency (CVI), including inherited
alterations in vein wall morphology, susceptibility to ve-
nous hypertension, and the influence of environmental
factors. The phenotypes and genetic material of patients
with CVD would optimally be correlated with CEAP clas-
sification and duplex ultrasound studies. The identification
of genes associated with venous disease will need to be
performed in collaboration with epidemiological studies in
centers for genetic research.The most useful diagnostic tools currently available are
duplex ultrasonography, plethysmography, contrast venogra-
phy, magnetic resonance venography (MRV) and computed
tomography (CT). However, all have limitations and the
severity of symptoms does not correlate with methods cur-
rently used to evaluate reflux and obstruction. The ideal
imaging study should precisely localize and quantify reflux
and obstruction within the deep, superficial, and perforator
venous systems (global and segmental). Such a test should also
be portable, cost effective, highly reproducible, and predictive
of long-termoutcome. Awireless device that can be applied at
rest and enable real-time study during activity (equivalent to
exercise ankle-brachial index (ABI) in arterial disease) as well
as treatment simulation (eg, temporary superficial venous
occlusion to predict outcome of saphenous ablation) would
be optimal. Duplex ultrasonography and magnetic resonance
imaging (MRI) are currently the most likely candidates for
further development, but these may be replaced by other
imaging modalities in the future.
The primary goal of surgical therapy is to improve venous
insufficiency through the obliteration of major reflux path-
ways and relief from obstruction. Unfortunately, interven-
tions aimed at restoring deep valve competence are less suc-
cessful in secondary than in primary venous disease.39
Furthermore, open interventions, such as venous bypass and
valve repair, are performed only in highly specialized centers
by experienced surgeons. However, minimally invasive tech-
niques, potentially accessible to a broader group of specialists,
have emerged in the past several years and their further devel-
opment should be encouraged.
Specific research initiatives in secondary chronic
venous disease
External compression devices. Compression stock-
ings reduce edema, improve venous pump function, im-
pede venous reflux, and may improve arterial inflow.40-43
However, compliance is often poor due to too much or
little compression, difficulty in applying the stockings, dis-
comfort, and aesthetics. An improved understanding of the
hemodynamic effects of compression would allow it to be
targeted and optimized for the individual patient. This may
also allow design of more comfortable, easier to apply
stockings that achieve the desired hemodynamic effect.
Another approach to treatment of severe CVI associated
with valve dysfunction would be an “external” valve closure
compression pump that senses reflux and generates intermit-
tent pressure peaks synchronized with the calf pump and
specific for the degree of reflux and size of the leg. Such a
device must be portable, easy to use, respond to patient
movement and position, and give feedback to the physician.
Dedicated venous stents. Iliocaval obstruction can be
treated by percutaneous insertion of stents.44,45 However,
current available stents are not specifically designed for the
venous system and the development of in-stent restenosis
requires frequent reintervention. Development of dedi-
cated venous stents, including modular systems for the
iliocaval confluence, is a priority in the treatment of second-
ary CVD. The characteristics of such a stent should include
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bility, low thrombogenicity, and minimal in-stent re-steno-
sis. The development of such a stent will require further
investigation regarding stent-vein wall interactions, mech-
anisms of restenosis, and periprocedural pharmacotherapy.
Implantable venous valves. As discussed in the sec-
tion on secondary CVD, there have been extensive efforts
to develop a percutaneously implantable deep venous valve
and there is preliminary data regarding the use of acellular
valve xenografts in humans. However, late malfunction and
thrombosis continue to be a problem with current designs.
Further development of implantable venous valves is a
critical priority and will require a prosthetic that is non-
thrombogenic, nonimmunogenic, flexible, and adaptable
to all venous segments. Development of artificial biosyn-
thetic mechanical valves was also ranked as a high priority
by the SIR multidisciplinary consensus panel.46
COMPRESSION HOSIERY
The mission of the International Compression Club
(ICC) is to provide a forum in which medical experts
interested in compression therapy and representatives from
the manufacturers of compression devices can discuss con-
troversial issues and propose solutions. Much of the discus-
sion at the Pacific Vascular Symposium focused on the need
to standardize compression parameters and reporting.
General priorities in compression hosiery
Compression is a medical treatment, requiring a precise
knowledge of the dose (ie, pressure, stiffness) necessary to
achieve the desired effect. Manufacturers currently provide
a pressure range (mmHg) based on in vitro measurements,
as well as a designated compression class. Compression
classes vary according to national regulations and are not
comparable. The medical literature should abandon use of
“compression classes”, reporting the range of pressure in
mm Hg and the method of measurement. Prescribing
compression stockings on the basis of compression ranges,
rather than classes, is also recommended.
There is a need to further evaluate current methods of
pressure measurement, both in vivo and in vitro, with
respect to the variability and reproducibility of different
techniques. Compression stockings from all manufacturers
should be independently evaluated using the three most
common methods (Hatra, ITF, and Hosy).47
Stiffness, which is defined as the pressure change gen-
erated by an increase in the transverse stretch of the stock-
ing, is not regularly declared by manufacturers. Use of the
same method for designation of pressure and stiffness
would be desirable in the future.
There is also a need to standardize the marketing of
compression bandages. As a minimum requirement, com-
plete information regarding the constituents (composi-
tion), stretchability (elasticity), adhesion (cohesive, adhe-
sive, or nonadhesive), and dimensions should be provided
on the packaging. With respect to elasticity, the following
terminology is recommended:● No stretch 0% to 10% inelastic
● Short-stretch 100% inelastic
● Long stretch 100% elastic
Scientific reports utilizing compression bandaging
should further define the application technique (eg, spiral,
figure-of-8, Putter, etc), the degree of bandage overlap, the
number of layers, the experience of the practitioner, and the
pressure delivered. The pressure may be measured at vari-
ous specified sites, but site B1 (gaiter area) is recommended
as the standard for recording in vivo compression.48 Pres-
sure levels should be reported as follows:49
● Light 20 mm Hg
● Medium 20 to 40 mm Hg
● Strong 40 to 60 mm Hg
● Extra strong 60 mm Hg
Future innovations in compression bandaging should
be directed towards medicated bandages; sprays applied
after application to modify fixation, cohesion, and stiffness;
newmaterials to improve comfort and compliance; pressure
monitoring devices incorporated into bandaging; the com-
bination of compression bandaging with intermittent
pneumatic compression (IPC); and air- and water-filled
devices.
The role of IPC in the treatment of deep venous
thrombosis, edema, venous ulcers, combined arterial/ve-
nous ulcers, and causalgia also needs further definition.
More definitive studies on the role of IPC in thrombopro-
phylaxis are also needed. Future studies should focus on
important clinical endpoints as well as the effect of IPC on
markers of coagulation, fibrinolysis, inflammation, and an-
giogenesis.
IMUA–THE FUTURE OF VENOUS DISEASE
The goals of the Fifth Pacific Vascular Symposium were
to establish the current state of knowledge in acute and
Table I. Organizational initiatives of the Pacific Vascular
Symposium
Initiative Goals
Joint Venous Council To form a new organization
with the goals of
● Increasing awareness about
venous disorders among
physicians and the public




Redefinition of the American
Venous Forum as a broad-
based, inclusive organization
● The achieve influence
through critical mass and
clinical/ scientific excel-
lence
● To act as a project/grant
clearinghouse
● To create evidence-based
practice guidelineschronic venous disease and develop a 10-year plan for
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tions of the meeting proceedings, the first part of this goal,
establishing the current state of knowledge, was success-
fully accomplished. Additionally, several organizational and
investigative priorities were established, initial protocols
developed, and experts recruited to participate in the indi-
vidual projects. Perhaps most importantly, definitive plans
were made to guide overall progress and identify priorities
for AVF support through establishment of an IMUA (Ha-
waiian for moving forward in a positive direction) commit-
tee.
The committee has distilled the initiatives generated by
Table II. Research initiatives of the Pacific Vascular Symp
Initiative
Evaluation of venous outflow obstruction To ex
qua














Biomarkers in diagnosis and prognosis of DVT To ev
bio
reg
Core-lab consortium and genetic database ● Cre
itat
● To










IVC filters in high-risk patients ● To
lan
Endovenous valves and venoscopic valve repair ● To
abl
● To
Pathophysiology of CVD To as
am
ulc









Functional venous testing ● To
ing
DVT, Deep venous thrombosis; CVD, chronic venous disease.the four working groups into two organizational (Table I) and13 investigative projects (Table II), each with an appointed
volunteer coordinator. Some validation of the importance of
the research initiatives is provided by the observation that
many similar projects were ranked as a high priority by an
independent multidisciplinary consensus panel organized by
the SIR.6,46 As discussed above, the ability to accomplish
these projects will require innovative approaches to funding
including partnerships with TheNational Institutes of Health
(NIH) and other governmental agencies, industry, the Amer-
ican Venous Forum, and other interested societies. Initial
investigator’s meetings are currently underway, and it is antic-
ipated that draft protocols and funding proposals will be
Goals
the use of magnetic resonance venography in the evaluating and
ing venous outflow obstruction
ate the utility of a single color-flow duplex exam, including the
s, in excluding DVT
e standard scanning protocols
uce guidelines for the diagnosis of DVT
ate the natural history of DVT in relation to thrombus charac-
e the role of early thrombus removal in the management of acute
ter, international randomized clinical trial
ical, pharmacological and surgical thrombectomy arms
for thrombus location (iliofemoral vs femoropopliteal)
e clinical and quality of life outcome measures
e the utility of coagulation, fibrinolytic, and inflammatory
ers in diagnosing DVT and providing prognostic information
g type and duration of therapy
of a specimen bank (vein, skin, blood) with clinical data to facil-
D research
ify markers predicting susceptibility and disease progression
ardize acute and chronic venous disease testing
lop uniform testing protocols
e normal ranges and significant variations
ify a standard for quality of life and hemodynamic outcomes
ify patterns of reflux that correlate with CEAP categories
ify patterns of reflux predicting progression to CEAP 4 to 6
ify patterns of reflux predicting success after intervention
lop a severity score for valvular incompetence
are strategies of permanent filters, removable filters, and surveil-
patients with trauma and intracerebral hemorrhage
lop a nonthrombogenic, nonimmunogenic, flexible and adapt-
sthetic venous valve
lop minimally invasive techniques to restore valve function
he role of the endothelium and identify mechanisms of
ry venous hypertension, inflammatory skin changes, and
n in animal and clinical models
a compression device to treat advanced CVD
and easy to use
s to patient position and movement
physician feedback
e a dedicated venous stent with greater radial strength and low
genicity
cterize the vein wall reaction to stents
ify mechanisms of restenosis
ify the role of periprocedural pharmacotherapy
















































exercdeveloped within the next year. Further information, includ-
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able on the American Venous Forum website (http://www.
venous-info.com/).
Despite the progress made during the Fifth Pacific
Vascular Symposium and the importance of these individ-
ual initiatives, the broader goal of defining a 10-year plan
for the advancement of venous disease was only partially
accomplished and should continue to be addressed in fu-
ture meetings.
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